The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

The discovery of biomarkers such as phospho-tau217 marked an important advancement in Alzheimer’s diagnosis. This particular ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Stock markets bounced higher on Tuesday following a huge sell-off, but analysts warned of more turmoil as US President Donald ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

The legislation would require insurance plans provided through the state’s system to cover FDA-approved treatments for ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...